ZTI BIOSCIENCES is a pioneering brand at the forefront of developing new technologies in the field of theragnostic oncology. By combining their own original nanotechnology platform with biotech, ZTI BIOSCIENCES is revolutionizing cancer care by creating next-generation therapeutic radiopharmaceuticals for intractable and recurring solid cancers. With their Nano Platform technology called TERACARRIER TM, ZTI BIOSCIENCES is unlocking the full potential of radioisotopes, standardizing radiopharmaceuticals, and offering innovative solutions for various indications in the challenging area of intractable oncology.

ZTI BIOSCIENCES also boasts an impressive history, including establishing their first R&D center, completing series A investment, and setting up a branch in Indianapolis, USA for the production of drugs. They have collaborated with prestigious institutions such as Harvard Medical Center and Bundang SNU Hospital, and have received recognition and awards for their groundbreaking work in the field. With a dedicated team of experts and a commitment to pushing boundaries, ZTI BIOSCIENCES is leading the way in advancing the fight against cancer.

Contact them today to learn more about their products and services